SYM 2189

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: SYM 2189
• 英文别名: 4-(4-aminophenyl)-6-methoxy-1-methyl-N-propyl-1H-phthalazine-2-carboxamide
• 化学式: C₂₀H₂₄N₄O₂
• 分子量: 352.436
• InChiKey: HONGXMZKVFQXBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  80
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(4-acetylaminophenyl)-7-methoxyphthalazine 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 生成 SYM 2189
  参考文献：
  名称：

  Allosteric modulators of the ampa receptor: Novel 6-substituted dihydrophthalazines

  摘要：

  Novel analogs of the allosteric AMPA receptor modulator SYM 2206 have been prepared. Structure/activity correlations of these novel analogs and other dihydrophthalazines (DHPs) reveal the important contribution of the heteroatom-based aryl substituents in this class of noncompetitive inhibitors. One of the analogs (6, SYM 2189) is equipotent with the early series, but with reduced sedation. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00044-x

文献信息

• 1H-QUINAZOLINE-2,4-DIONES
  申请人：NOVARTIS AG

  公开号：US20130296332A1

  公开（公告）日：2013-11-07

  The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R 1 and R 2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

  本发明涉及公式(I)的1H-喹唑啉-2,4-二酮，其中R1和R2如规范所定义，它们的制备，它们作为药物的用途，以及含有它们的药物组合物。此外，还公开了制造公式(I)化合物的中间体和包含公式(I)化合物的组合物。
• 1H-Quinazoline-2,4-Diones
  申请人：Allgeier Hans

  公开号：US20080153836A1

  公开（公告）日：2008-06-26

  The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R 1 and R 2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

  本发明涉及公式（I）的1H-喹唑啉-2,4-二酮，其中R1和R2如规范中所定义，它们的制备，它们作为药物的用途以及含有它们的药物组合物。此外，还揭示了制造公式（I）化合物的中间体和包含公式（I）化合物的组合物。
• 1H-QUINAZ0LINE-2,4-DIONES
  申请人：ALLGEIER Hans

  公开号：US20100144747A1

  公开（公告）日：2010-06-10

  The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R 1 and R 2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

  本发明涉及式(I)的1H-喹唑啉-2,4-二酮，其中R1和R2如规范中所定义，它们的制备，它们作为药物的用途以及包含它们的制药组合物。此外，还披露了制备式(I)化合物的中间体和包含式(I)化合物的组合物。
• Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases
  申请人：Novartis AG

  公开号：EP2213285A2

  公开（公告）日：2010-08-04

  Disclosed is a new use for sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent, preferably selected from an AMPA receptor agonist, a nootropic agent, a painkiller and an anti-inflammatory agent in the treatment of progressive dementia or brain degenerative diseases.

  所公开的是鞘氨醇-1-磷酸（S1P）受体激动剂与第二种药剂（最好选自 AMPA 受体激动剂、促神智药、止痛药和抗炎药）联合用于治疗进行性痴呆或脑变性疾病的一种新用途。
• 1H-Quinazoline-2,4-diones
  申请人：Novartis AG

  公开号：EP2468732A1

  公开（公告）日：2012-06-27

  The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.

  本发明涉及式 (I) 的 1H-喹唑啉-2,4-二酮 其中 R1 和 R2 如说明书中所定义、它们的制备、它们作为药物的用途以及含有它们的药物组合物。此外，还公开了用于制造式 (I) 化合物的中间体以及包含式 (I) 化合物的组合物。